The biotechnology company Lysando has agreed a development contract with the South Korean firm Amicogen. The aim here is for Amicogen to accelerate the further development of Lysando’s antimicrobial proteins to bring them to market maturity.

The two biotechnology firms Lysando and Amicogen are deepening their collaboration within the framework of a general development contract. The partnership should help Lysando, based in Triesenberg in Liechtenstein, to bring its proprietary developments to market maturity as quickly as possible and therefore accelerate the company’s entry into the pharmaceutical industry, further details of which can be found in a press release.

According to Count Markus Matuschka von Greiffenclau, Chairman of the Board of Directors of Lysando AG, the Jinju-based Amicogen is “always our first choice for process development and to scale-up new artilysins”. These are antimicrobial proteins that can eliminate bacteria in urinary tract infections, for example, without developing resistance.

Prior to agreeing this general development contract, the two companies had been collaborating closely as part of a mutual participation model since August 2021.

Amicogen develops and manufactures specialty enzymes and proteins for the biopharmaceutical, food and cosmetic industries, among others. The listed company should help Lysando to “bring proprietary developments to market maturity as quickly as possible, thereby further accelerating entry into the pharmaceutical industry”, the press release explains.

Back to overview